Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Office of Translational Research


The mission of the NINDS Office of Translational Research (OTR) is to facilitate the preclinical discovery and development of new therapeutic interventions for neurological disorders.

Announcements:

06/10/14  The Office of Translational Research welcomes three new Scientific Project Managers, Drs. Shamsi Raeissi, Chris Boshoff and Mary Ann Pelleymounter.

04/15/14  Redesign of Office of Translational Research Programs

12/06/13  The Anticonvulsant Screening Program launches the Public Access to Neuroactive & Anticonvulsant Chemical Evaluations(PANAChE) website

10/23/13  Video: Liftware featured on Doctors TV Show (NINDS supported)

10/22/13  Tetra Discovery Partners Reaches New $1 Million Strategic Funding Milestone With Grand Angels-Led Investment

08/08/13  Video: Dr. Rajesh Ranganathan Explains the NIH Blueprint Neurotherapeutics Network

05/20/13  The Small Business Program now has a twitter account: @NINDS_SmallBiz

The Office of Translational Research will be at the National SBIR Conference and the BIO International Convention in June, 2014.


Therapeutic Development Programs

View mode:




 

  • Anticonvulsant Screening Program (ASP)

    • Provides services to characterize, optimize, and profile novel antiseizure/anticonvulsant agents by using a battery of disease-specific and mechanistic models of epilepsy (NINDS)
  • Translational R21 (all modalities)

    • Provides funding (R21) for preclinical development tasks, including creation and validation of screening assays, development of animal models for therapy development, identification of candidate therapeutics, and development of preliminary animal efficacy data (NINDS)
  • CREATE Bio for Biotechnology Products and Biologics

    • Provides cooperative agreement funding (U01, UH2/UH3, U44) for discovery and development of therapeutic Biotechnology Products and Biologics (e.g. peptides, proteins, oligonucleotides, gene therapies, and cell therapies) for disorders that fall under the NINDS mission.
  • CREATE Devices Coming Soon

    • Provides cooperative agreement funding (UH2/UH3, U44) to support projects that focus on pre-clinical and pilot clinical studies for therapeutic devices.
  • Small Business Program: SBIR & STTR

    • Provides funding (R41, R42, R43, R44, U44) to small businesses to engage in research and development with the potential for commercialization (NINDS)
  • Blueprint Neurotherapeutics Network for Small Molecules

    • Provides cooperative agreement funding (UH2/UH3) and free access to millions of dollars-worth of contracted drug development services and expertise to transform small molecule probe compounds into drug candidates for diseases and disorders of the nervous system (Trans-NIH)
  • High Throughput Screening to
    Discover Chemical Probes

    • Provides research grant funding (R01) to encourage investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes.
  • BrIDGs

    • BrIDGs makes available certain critical resources needed for the development of new therapeutic agents. (Trans-NIH)
  • Countermeasures Against Chemical Threats (CounterACT)

    • Provides funding (U01, U54, R21, U44, contracts) and research services to develop products to prevent, diagnose, and treat the conditions caused by exposure to toxic chemicals (Trans-NIH)

Legend

  •  NINDS
  •  Trans-NIH


Office of Translational Research Funding Initiatives


Office of Translational Research Active Projects

 

Office of Translational Research Program Staff


 

Scientific StaffResearch Area
Rajesh Ranganathan, Ph.D.
Associate Director

 
 
Rebecca Farkas, Ph.D.
Program Director

 
Blueprint Neurotherapeutics Network, Medicinal Chemistry, Roadmap Molecular Libraries
David Jett, Ph.D.
Program Director

 
Countermeasures (CounterACT) Programs, Neurotoxicology, Roadmap Molecular Libraries
Karrah Benson, B.S.
Program Coordinator

 
Anticonvulsant Screening Program (ASP)
Chris Boshoff, Ph.D.
Scientific Project Manager

 
Cooperative Agreement Program (CAP)
Tracy Chen, Ph.D., D.A.B.T.
Scientific Project Manager

 
Anticonvulsant Screening Program (ASP)
Charles Cywin, Ph.D.
Project Manager

 
Blueprint Neurotherapeutics Network
Stephanie Fertig, MBA
Research Project Manager

 
Small business (SBIR, STTR)
Adrienne Ivory, M.S.
Program Analyst

 
Blueprint Neurotherapeutics Network
John Kehne, Ph.D.
Program Director

 
Anticonvulsant Screening Program (ASP), Cooperative Agreement Program (CAP)
Linda McGavern, Ph.D.
Project Manager

 
NINDS Cooperative Program in Translational Research
Margaret Ochocinska, Ph.D.
Health Program Specialist

 
Anticonvulsant Screening Program (ASP), Countermeasures (CounterACT) Programs
Mary Ann Pelleymounter, Ph.D.
Scientific Project Manager

 
 
Shamsi Raeissi, Ph.D.
Scientific Project Manager

 
Anticonvulsant Screening Program (ASP)
Rebecca Roof, Ph.D.
Health Program Specialist

 
Small Business (SBIR, STTR)
Shalini Sharma, M.S.
Project Coordinator

 
Anticonvulsant Screening Program (ASP)
Amir Tamiz, Ph.D.
Program Manager

 
Blueprint Neurotherapeutics Programs
Christina Vert, M.S.
Health Program Specialist

 
NINDS Cooperative Program in Translational Research
Patricia Walicke, MD, Ph.D.
Medical Officer

 
 
Hao Wang, Ph.D.
Program Director

 
Cooperative Agreement Program (CAP)
David Yeung, Ph.D.
Program Specialist/Project Manager

 
Countermeasures (CounterACT) Programs